company background image
GILD

Gilead Sciences NasdaqGS:GILD Stock Report

Last Price

US$75.27

Market Cap

US$93.8b

7D

-0.5%

1Y

19.7%

Updated

22 Sep, 2023

Data

Company Financials +

GILD Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILD fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance5/6
Financial Health4/6
Dividends3/6

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share PriceUS$75.27
52 Week HighUS$89.74
52 Week LowUS$61.45
Beta0.39
1 Month Change-2.30%
3 Month Change-2.84%
1 Year Change19.74%
3 Year Change20.92%
5 Year Change-2.51%
Change since IPO11,794.53%

Recent News & Updates

We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt

Aug 11
We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt

Recent updates

We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt

Aug 11
We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt

Here's Why Gilead Sciences (NASDAQ:GILD) Has Caught The Eye Of Investors

Jul 04
Here's Why Gilead Sciences (NASDAQ:GILD) Has Caught The Eye Of Investors

Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year

Jun 13
Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75

May 30
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.75

May 16
Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.75

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

May 02
Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet

Apr 17
Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Feb 21
Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Gilead Sciences (NASDAQ:GILD) Will Pay A Larger Dividend Than Last Year At $0.75

Feb 07
Gilead Sciences (NASDAQ:GILD) Will Pay A Larger Dividend Than Last Year At $0.75

Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 41% Discount?

Dec 05
Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 41% Discount?

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Nov 16
These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Gilead's Kite gains license to Refuge Biotechnologies platform for blood cancer treatments

Oct 20

Gilead's Quality And Growth Potential Are Underappreciated

Oct 14

Gilead Sciences: Becoming A Cure

Oct 03

A Dive Into Gilead Sciences' New HIV Medication

Sep 22

Gilead Sciences goes ex-dividend tomorrow

Sep 13

Gilead Sciences: Don't Miss The Transformation

Sep 01

Gilead Is Too Cheap To Ignore And Set To Soar

Aug 21

Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite Sensibly

Aug 18
Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite Sensibly

Shareholder Returns

GILDUS BiotechsUS Market
7D-0.5%-0.5%-1.5%
1Y19.7%10.8%13.8%

Return vs Industry: GILD exceeded the US Biotechs industry which returned 10.8% over the past year.

Return vs Market: GILD exceeded the US Market which returned 13.8% over the past year.

Price Volatility

Is GILD's price volatile compared to industry and market?
GILD volatility
GILD Average Weekly Movement2.8%
Biotechs Industry Average Movement9.0%
Market Average Movement5.6%
10% most volatile stocks in US Market14.3%
10% least volatile stocks in US Market2.5%

Stable Share Price: GILD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: GILD's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198717,000Dan O'Dayhttps://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILD fundamental statistics
Market CapUS$93.79b
Earnings (TTM)US$5.48b
Revenue (TTM)US$27.38b

17.1x

P/E Ratio

3.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GILD income statement (TTM)
RevenueUS$27.38b
Cost of RevenueUS$5.63b
Gross ProfitUS$21.75b
Other ExpensesUS$16.26b
EarningsUS$5.48b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)4.40
Gross Margin79.42%
Net Profit Margin20.03%
Debt/Equity Ratio119.7%

How did GILD perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

68%

Payout Ratio